Increased Levels of hsa-miR-199a-3p and hsa-miR-382-5p in Maternal and Neonatal Blood Plasma in the Case of Placenta Accreta Spectrum
2024

Increased Levels of Specific MicroRNAs in Maternal and Neonatal Blood Plasma in Cases of Placenta Accreta Spectrum

Sample size: 160 publication 10 minutes Evidence: high

Author Information

Author(s): Timofeeva Angelika V., Fedorov Ivan S., Nikonets Anastasia D., Tarasova Alla M., Balashova Ekaterina N., Degtyarev Dmitry N., Sukhikh Gennady T.

Primary Institution: National Medical Research Center for Obstetrics, Gynecology and Perinatology Named After Academician Kulakov V.I.

Hypothesis

This study investigates whether there are changes in the blood plasma microRNA levels of premature infants born to mothers with placenta accreta spectrum compared to infants of similar gestational age born to mothers without placenta accreta spectrum.

Conclusion

The study found significant increases in hsa-miR-199a-3p and hsa-miR-382-5p levels in the blood plasma of newborns from mothers with placenta accreta spectrum, which are associated with respiratory complications.

Supporting Evidence

  • A significant increase in hsa-miR-199a-3p and hsa-miR-382-5p levels was observed in the blood plasma of newborns from mothers with PAS compared to the control group.
  • Logistic regression models predicted the need for cardiotonic therapy and invasive mechanical ventilation in newborns with high sensitivity.
  • Direct correlations were found between miRNA levels and clinical parameters such as oxygen requirements in the NICU and duration of NICU stay.

Takeaway

This study shows that babies born to mothers with a certain pregnancy complication have higher levels of specific tiny molecules in their blood, which might affect their breathing.

Methodology

MicroRNA profiling was performed using small RNA deep sequencing and quantitative real-time PCR on blood plasma samples from preterm infants and their mothers.

Potential Biases

Potential biases may arise from the sample selection and the observational nature of the study.

Limitations

The study does not address the long-term outcomes of the elevated microRNA levels in newborns.

Participant Demographics

The study included preterm infants (gestational age: 33–36 weeks) and their mothers diagnosed with or without placenta accreta spectrum.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.3390/ijms252413309

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication